We are live on ! Find out more

MacroGenics

MGNX

Market cap $255M

4.00 USD

+0.03

0.76%

At close Updated Sep 11, 4:00 PM EDT

1 day

0.76%

5 days

-4.76%

1 month

2.04%

3 months

-0.25%

6 months

19.76%

Year to date

148.45%

1 year

142.42%

5 years

-85.35%

10 years

-86.43%

About: Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Employees: 293

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 54.5%

Negative 9.1%

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with multiple near-term catalysts to drive potential upside. Gilead's recent activity on multiple TCEs and MacroGenics' negative enterprise value suggest partnership is under appreciated & undervalued.

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

Zacks Investment Research

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.57 per share a year ago.

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress.

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics.

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges.

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon's two-stage design Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug conjugate (ADC), incorporating a topoisomerase I inhibitor-based linker-payload, in patients with advanced solid tumors. MacroGenics plans to present dose escalation and preliminary tumor-specific cohort results at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23-27, 2026, in Madrid, Spain.

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

Zacks Investment Research

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, today announced completion of the sale of MacroGenics' good manufacturing practice (GMP) drug substance manufacturing operations to Bora.

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

See News Rankings

Price charts implemented using Lightweight Charts™